Prior authorization required — document wound, ≥4 weeks conservative care, wound characteristics

Prior authorization is required for listed cellular and tissue-based products (CTPs) for DFU and VLU. Requests must identify the specific wound, document at least four weeks of prior conservative wound care, describe wound characteristics and treatment plan, confirm absence of contraindications, and specify the requested product/HCPCS/Q-code and justification for initial or continued applications.

• Request must indicate the specific wound to which the CTP will be applied (chunk 5).
• Documented ≥4 weeks of standard conservative therapy and failure (wound area reduced by <50% in 4 weeks) (chunk 5).
• Include product identification (HCPCS/Q-code, package label or NDC) and justification for initial or continued applications (chunks 8, 11).

Prior authorization — document no infection and risk‑factor optimization (smoking cessation)

Prior authorization requests for listed products and indications must document absence of wound infection and that modifiable risk factors have been addressed (including smoking cessation counseling or completion where applicable), and must specify the selected product from the listed HCPCS/Q-codes.

• No evidence of wound infection required for covered indications (chunks 18, 21).
• Documentation that modifiable risk factors are being addressed and smoking cessation counseling/completion when applicable (chunks 18, 21).
• Product requested must be one of the listed HCPCS/Q-codes for the indication (chunk 18).

Specify product for annotated HCPCS entries — may require prior authorization

Certain HCPCS entries in the policy tables are annotated with an asterisk and require that the provider specify the exact product on the claim or authorization; product-specified entries may trigger prior authorization or require product identification to support medical necessity.

• Products marked with an asterisk must be specified as noted in the HCPCS table (chunk 46).
• Examples include annotated entries such as A4100*, C1781*, Q4431*, Q4433* that require product specification (chunks 45–46).

Prior authorization — initial up to 4 applications; continuation up to total 8

Prior authorization decisions follow the staged approval limits in the policy: up to four initial applications are authorized, with continuation requests considered up to a total of eight applications per wound within a 12-week episode when continuation criteria are met.

• Initial approval: up to four applications for DFU and VLU when criteria are met (chunk 5).
• Continuation: requests beyond initial four considered up to total of eight applications per 12-week episode with documentation of response and medical necessity (chunks 9, 66).

Prior authorization — consult applicable CMS LCDs and articles

Consult applicable CMS local coverage determinations (LCDs) referenced by the policy when making authorization decisions; the policy cites LCDs and a Local Coverage Article that inform coverage rules and coding guidance.

• Referenced LCDs include L36690, L35041, L36377 and Local Coverage Article A56696 (chunk 72).
• For Medicare members, review applicable NCDs/LCDs and Medicare Coverage Articles prior to applying policy criteria (chunk 97).

Check NCDs/LCDs and plan coverage documents before authorizing

Before authorizing CTPs for Medicare members, review all applicable Medicare NCDs, LCDs, and plan coverage documents; adherence with CMS determinations may be required for coverage.

• Note to review Medicare NCDs/LCDs for consistency with this clinical policy prior to applying criteria (chunk 97).
• CMS references cited in the policy should be checked for updates (chunk 72).

Document wound preparation prior to CTP — use preparation code at least once

Authorization should confirm that appropriate wound preparation was performed and coded at least once prior to CTP placement; repeat billing for surgical preparation services with skin substitute application codes is not considered reasonable and necessary.

• Each wound is expected to have at least one appropriate wound preparation code used at initiation of care prior to placement of the skin substitute graft (chunk 13).
• Repeat use of surgical preparation services in conjunction with skin substitute application codes is considered not reasonable and necessary (chunk 13).

Confirm standard wound care applied and documented before CTP

Ensure standard wound care measures were applied and documented before CTP use: infection control, debridement, offloading/compression, edema management, and systemic disease management must have been attempted and documented.

• Policy requires demonstration that standard wound-care measures including debridement, standard dressings, compression, and off‑loading were used (chunk 5).
• Background highlights infection control, edema management, offloading/compression, debridement, and systemic disease management as standard care prior to CTPs (chunk 25).

Staged approval — initial up to 4, continuation to total up to 8 with justification

Staged application approvals: initial authorization typically covers up to four applications; continuation requests must document clinical response and justification to support approval up to a total of eight applications within a 12-week episode.

• Initial approved quantity: up to four applications (chunk 66).
• Continuation up to a total of eight applications per 12-week episode requires documentation of response to initial applications and rationale for further applications (chunk 9).

Required documentation per application — photos, measurements, procedure note, product name/label/NDC, wastage details

For each application, maintain comprehensive documentation in the medical record: baseline and follow-up wound photos/measurements, complete procedure description including product name/label or NDC and size, amount used and amount wasted with date/time/reason, and manufacturer lot/serial information.

• Graphic evidence of wound size, depth, and characteristics at baseline and follow-up with measurements (chunks 8, 11).
• Complete procedure description including product used with package label or NDC and size (chunks 8, 11).
• Document amount administered and wasted, date/time and reason for wastage, and manufacturer lot/serial/batch identification when available (chunks 8, 13).
• All documentation must be maintained in the member's medical record and made available upon request (chunks 8, 12).

Per-application baseline and follow-up photos plus full procedure documentation

Document baseline and follow-up graphic/photo evidence and full procedure documentation for every application, including rationale for chosen product size to minimize wastage and evidence that criteria for continued therapy are met.

• Graphic evidence and measurements at baseline and follow-up (chunk 20).
• Procedure note must include product NDC/label, size, and rationale for chosen size to minimize wastage (chunk 22).
• Continuation requests must explain how initial treatment resulted in healing progress and why additional applications are medically necessary (chunk 9).

Record retention and billing for discarded single‑use product — document amount wasted and retained

Maintain records of product use and wastage; when a single-use package is partially discarded, document amount applied and wasted and, where applicable, payment may be made for the discarded portion up to the package amount.

• Document amount administered and wasted, date/time and reason for wastage, and manufacturer lot number (chunks 12, 13).
• Payment may be made for portion discarded along with amount applied up to product package amount (chunks 12, 19).
• All records must be maintained in the medical record and provided upon request (chunks 12, 19).

Use current coding sources and specify product when required (*)

Use current CPT and HCPCS coding sources when submitting authorizations and claims; include product specification when the HCPCS/Q-code table notes that the product must be specified (products marked with an asterisk).

• Codes in the policy are informational; providers must reference up-to-date CPT/HCPCS manuals prior to claim submission (chunk 39).
• Products marked with an asterisk in HCPCS tables must be specified to support medical necessity (chunk 46).

Supply required documentation and product lists as requested under criteria II

Comply with the policy's documentation requirements referenced under the coverage criteria; providers may be asked to supply product lists for DFU and VLU and must maintain required records to support medical necessity.

• Policy includes documentation requirements under criteria II and may request product lists for DFU and VLU (chunk 63).
• Providers must supply the documentation specified in the policy for each application (chunk 66).

Follow CMS LCDs and local billing/coding guidance when documenting and coding

Follow CMS LCDs and billing guidance cited in the policy for documentation and coding; authorization and claims should align with the referenced LCDs and local billing articles.

• Documentation and coding should follow the cited CMS LCDs and the Local Coverage Article A56696 (chunk 72).
• For Medicare patients, ensure consistency with relevant NCDs/LCDs prior to applying policy criteria (chunk 97).

Document medical necessity and consider member contract/ regulatory terms

Providers must document medical necessity, exercise professional judgment, and recognize that coverage determinations are also subject to member contract terms, state and federal rules, and Health Plan administrative policies.

• Providers are expected to exercise professional medical judgment and document medical necessity (chunk 96).
• Coverage decisions are subject to member contracts, state Medicaid provisions, and federal requirements (chunk 95).

Common denial scenarios — partial‑thickness with appendages, simultaneous products, repeat/retreatment exclusions

Common denial scenarios include use for partial‑thickness wounds with retention of epithelial appendages, simultaneous use of more than one product in an episode, repeat or alternative applications after an unsuccessful full course, retreatment of healed ulcers, and re-treatment within one year for VLU/DFU.

• Partial thickness loss with retention of epithelial appendages is not medically necessary (chunk 12).
• Simultaneous use of >1 product in a wound episode is not allowed (chunks 8, 11).
• Repeat/alternative applications after an unsuccessful prior full course and retreatment of healed ulcers (>75% reduction and <0.5 cm2) are not medically necessary (chunk 12).
• Re-treatment within one year for a given course in VLU or DFU is not medically necessary (chunk 12).

Denial risk — requests >12 weeks or repeat applications after unsuccessful initial course

Requests for treatment longer than twelve weeks or repeat applications after an initial treatment was unsuccessful for a period of four weeks past the start of therapy are considered not medically necessary and may be denied.

• Treatment durations exceeding 12 weeks are considered not medically necessary (chunk 24).
• Repeat applications after unsuccessful initial treatment (no improvement or worsening for 4 weeks past start of therapy) are not medically necessary (chunks 24, 9).

Coding guidance is informational — incorrect or outdated coding risks denial

Coding lists in the policy are informational and inclusion or exclusion of codes does not guarantee coverage; use of incorrect or outdated codes may result in claim denial.

• Codes referenced in the clinical policy are for informational purposes only and inclusion/exclusion does not guarantee coverage (chunk 40).
• Providers should reference current coding guidance prior to claim submission to avoid denial for incorrect coding (chunk 39).

Risk of denial for coding/criteria mismatch — use listed HCPCS codes that match product and indication

Use of HCPCS codes not listed in the policy tables that support medical necessity, or billing codes that do not match documented clinical criteria, may lead to noncoverage or denial; ensure coding aligns with the product and indication criteria.

• The policy reorganized HCPCS tables; use codes from the tables that support medical necessity for the specific indication (chunk 66).
• Failure to use HCPCS codes that correspond to the product/indication or mismatch between coding and clinical criteria may result in denial (chunks 65, 66).

CMS LCD alignment required — check referenced LCDs/LCAs to avoid denial

Authorization and billing that conflict with applicable CMS LCDs, NCDs, or cited billing articles may trigger denial; verify alignment with the referenced CMS determinations before authorizing or billing.

• Use or billing that conflicts with applicable CMS local coverage determinations or billing/coding articles may trigger denial (chunks 72, 97).
• Review the cited LCDs and Local Coverage Article to ensure authorization and claims align with CMS guidance (chunk 72).

Denial risk — policy or contract exclusions and state/federal requirements may override coverage

Coverage is governed by member coverage documents and state/federal requirements; services excluded by contract or by state/federal rules may be denied even if policy criteria are met.

• Coverage decisions are subject to the terms, conditions, exclusions and limitations of the member's coverage documents and to state and federal requirements (chunk 95).
• This clinical policy does not guarantee payment; the Health Plan may change, amend, or withdraw the policy (chunk 96).
• For Medicare members, consistency with NCDs/LCDs should be ensured (chunk 97).